98%
921
2 minutes
20
Background: Depression is a common psychiatric condition and an independent stroke risk factor among people with HIV (PWH). The impacts of depressive symptom severity on stroke are not clear in PWH.
Methods: We studied adult PWH in clinical care at five CNICS sites with ≥1 assessment for depressive symptoms (PHQ-9) from 2010-2022. We used Cox models to evaluate: (1) associations between time-varying depressive symptom severity and adjudicated incident stroke, serially adjusted for clinical factors; (2) modification of this association by age and sex. Participants were followed from 6 months after first CNICS visit or date the CNICS site began stroke adjudication (baseline) (whichever later) until the first stroke, death, loss to follow-up, last clinic visit, or study end.
Results: Among 13,817 PWH (mean age 45 years, 19% female, 58% non-white race/ethnicity), 23% screened positive for depression at baseline and 173 had an incident stroke during follow up (mean follow-up 7.6 years). Time-varying depressive symptom severity (per 5-points PHQ-9 score) was associated with higher stroke risk (aHR 1.16, P=0.01) with greater impact in PWH <50y than ≥50y (Interaction P=0.02) but no significant difference by sex. Adjusting for combinations of sociodemographic, cardiovascular, HIV, and substance use factors only slightly attenuated estimates.
Conclusions: Depressive symptom severity was an independent risk factor for stroke with higher severity depressive symptoms predicting higher stroke risk and greater impact in PWH <50 years. Depression may be a modifiable risk factor for stroke and should be studied further to understand, develop, and target interventions to reduce stroke risk, especially in younger PWH.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12306592 | PMC |
http://dx.doi.org/10.1097/QAI.0000000000003710 | DOI Listing |
J Med Internet Res
September 2025
School of Pharmacy, Sungkyunkwan University, Gyeonggi-do, Republic of Korea.
Background: Owing to the unique characteristics of digital health interventions (DHIs), a tailored approach to economic evaluation is needed-one that is distinct from that used for pharmacotherapy. However, the absence of clear guidelines in this area is a substantial gap in the evaluation framework.
Objective: This study aims to systematically review and compare the economic evaluation literature on DHIs and pharmacotherapy for the treatment of depression.
JAMA Psychiatry
September 2025
Denovo Biopharma LLC, San Diego, California.
Importance: This study represents a first successful use of a genetic biomarker to select potential responders in a prospective study in psychiatry. Liafensine, a triple reuptake inhibitor, may become a new precision medicine for treatment-resistant depression (TRD), a major unmet medical need.
Objective: To determine whether ANK3-positive patients with TRD benefit from a 1-mg and/or 2-mg daily oral dose of liafensine, compared with placebo, in a clinical trial.
Neurochem Res
September 2025
Biology and Health Laboratory, Faculty of Sciences, Ibn Tofail University, Kenitra, Morocco.
Parkinson's disease (PD) is characterized by impairments in motor control following the degeneration of dopamine-producing neurons located in the substantia nigra pars compacta. Environmental pesticides such as Paraquat (PQ) and Maneb (MB) contribute to the onset of PD by inducing oxidative stress (OS). This study evaluated the therapeutic efficacy of moderate physical activity (PA) on both motor and non-motor symptoms in a Wistar rat model of Paraquat and Maneb (PQ/MB) induced PD.
View Article and Find Full Text PDFInfect Dis Ther
September 2025
Department of Nursing, Affiliated Hospital of Zunyi Medical University, Zunyi, 563000, China.
Introduction: Cognitive frailty (CF), which typically precedes dementia and functional decline, serves as a more robust predictor of adverse health outcomes compared to physical frailty alone, representing a critical challenge in promoting healthy aging among older people living with HIV (PLWH) aged ≥ 50 years. This study aimed to investigate the prevalence of cognitive frailty and identify its associated factors among PLWH aged ≥ 50 years.
Methods: A convenience sample of 344 PLWH ≥ 50 years was recruited from a tertiary Grade A hospital in Zunyi, China.
Int Urogynecol J
September 2025
Department of Public Health Sciences, University of Connecticut School of Medicine, Farmington, CT, USA.
Introduction And Hypothesis: Depressive and anxiety symptoms are known risk factors for lower urinary tract symptoms (LUTS). To inform prevention and treatment strategies, this research examined whether greater emotional support seeking weakened associations of affective symptoms with LUTS and poorer bladder health.
Methods: Data were collected from women in the USA who participated in the RISE FOR HEALTH study of bladder health.